Journal
CELL DEATH AND DIFFERENTIATION
Volume 15, Issue 12, Pages 1815-1823Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2008.135
Keywords
alternative splicing; apoptosis; E2F1; SC35; SR proteins
Categories
Funding
- Rhone Alpes
- Ligue contre le Cancer
- Ligue Nationale contre le Cancer
- INCa
- Conseil Scientifique National d'AGIR a dom
- French Research Ministry
- Fondation pour la Recherche Medicale (FRM)
Ask authors/readers for more resources
The transcription factor E2F1 has a key function during S phase progression and apoptosis. It has been well-demonstrated that the apoptotic function of E2F1 involves its ability to transactivate pro-apoptotic target genes. Alternative splicing of pre-mRNAs also has an important function in the regulation of apoptosis. In this study, we identify the splicing factor SC35, a member of the Ser-Rich Arg (SR) proteins family, as a new transcriptional target of E2F1. We demonstrate that E2F1 requires SC35 to switch the alternative splicing profile of various apoptotic genes such as c-flip, caspases-8 and -9 and Bcl-x, towards the expression of pro-apoptotic splice variants. Finally, we provide evidence that E2F1 upregulates SC35 in response to DNA-damaging agents and show that SC35 is required for apoptosis in response to these drugs. Taken together, these results demonstrate that E2F1 controls pre-mRNA processing events to induce apoptosis and identify the SC35 SR protein as a key direct E2F1-target in this setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available